

RETROSPECTIVE CHART REVIEW OF 79 SUBJECTS WITH GASTROESOPHAGEAL REFLUX DISEASE MANAGED WITH THE REFLUXSTOP PROCEDURE: A REPORT OF THE SAFETY AND EFFICACY

Christoph Oehler

UEG Week Copenhagen 2023

Poster

Oesophagus

October 15, 2023

A retrospective single-center study of 79 GERD patients treated with the RefluxStop device showed significant symptom improvement and reduced PPI use at 10.7 months follow-up with no severe complications.

KEY POINTS

- 79 subjects underwent the RefluxStop procedure at a single German institution between July 2021 and November 2022, with baseline characteristics including 57% hiatal hernia prevalence, 45.6% esophagitis, and mean PPI use of 4.7 years.
- At mean follow-up of 10.7 months, all subjects showed significant improvement in GERD symptoms including dysphagia, with no subjects requiring esophageal dilatation or reoperation.
- GERD-HRQL scores improved 92.6% from baseline (21.5 ± 5.2 to 1.6 ± 3.2), and only 2.5% of subjects required continued PPI therapy postoperatively.
- No severe perioperative complications occurred in this retrospective case series.
- The authors conclude that further studies are needed to validate the role of RefluxStop in GERD management.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/00661916-743d-11ee-bf46-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.